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Atopic Dermatitis: From 
Physiopathology to the Clinics
Ignasi Figueras-Nart and Oscar Palomares-Gracia
Abstract
Atopic dermatitis is a chronic, pruritic, relapsing inflammatory disease with a 
complex etiopathogenesis. Alterations of the epidermal barrier function together 
with a predominantly type 2 altered immune response are responsible for the het-
erogeneous clinical manifestation. Although pruritic eczematous plaques represent 
the most frequent phenotype, several others are also characteristic. The diagnostic of 
the disease relies on clinical aspects, and no complimentary tests are needed. In the 
literature, we can find a significant number of diagnostic and screening biomarkers; 
however, severity ones are the most reliable and applicable. Patient-tailored treatment 
is mandatory, as not all the patients equally respond to the same drugs. The newly 
released therapies, as well as those under investigation, give hope to AD patients.
Keywords: atopic dermatitis, immunology, type 2 immune response,  
clinical features, eczema, biomarkers, risk factors, treatment, biological agents
1. Introduction
Atopic dermatitis (AD) is a common chronic, pruritic, relapsing, inflammatory 
systemic disease that affects both children and adults. Patients frequently have high 
levels of total immunoglobin E (IgE) and a personal or family history of atopic-
related diseases.
AD is one of the most common inflammatory cutaneous diseases with an inci-
dence that has tripled in the last 3 decades in industrialized countries. Prevalence 
in children population is approximately 15–20%, while it is much lower in adults, 
between 1 and 3%.
Several studies demonstrate that AD has a high impact on patients’ quality of life 
(QoL). For some of them, the impairment in QoL is more significant than in some 
other chronic diseases such as hypertension, diabetes, or even psoriasis [1].
In this chapter, we will make a dual approach to AD. First, we will concentrate 
on the immunological mechanisms of AD and then will discuss the clinical and 
therapeutic aspects of the disease.
2. Immunological mechanisms of AD
2.1 Immunological mechanisms underlying atopic dermatitis
The immune system is a very complex and interactive network of cells and 
molecules to protect the host against potentially dangerous pathogens while 
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keeping at the same time a state of tolerance against self and innocuous non-self-
antigens [2, 3]. The immune system employs a large number of molecular and 
cellular mechanisms that must be tightly regulated to perform this vital function. 
Alterations on these mechanisms lead to the appearance of immune-related diseases 
such as recurrent infections, autoimmunity, tumor tolerance, organ rejection, as 
well as allergic and skin diseases such as AD [2, 4–6].
AD is one of the most prevalent chronic inflammatory diseases of the skin 
affecting both children and adults [7, 8]. The clinical features that characterize 
the disease are dry and scaly skin, eczema lesions, and chronic itching. AD is a 
very complex and debilitating disease that should be considered as a systemic 
disease associated with different comorbidities. The development of AD depends 
on the integration of multiple factors such as genetic background, environmental 
exposure, skin barrier, and immune alterations [9–11]. All these factors cooperate 
and synergize leading to the clinical manifestations of AD. Over the last years, our 
understanding on the immunological mechanisms underlying AD has significantly 
improved [12]. Today, it is well accepted that the inflammatory component of 
AD is mainly driven by aberrant type 2 immune responses, which significantly 
contribute also to barrier defects and itching [5, 13]. Other immune responses 
including Th17, Th22, and, to a lesser extent, Th1 cells can also contribute to AD at 
different stages of the disease as well as in different subsets of patients and pheno-
types [11, 14, 15].
2.2 Orchestration of type 2 immune responses
The immune system employs type 2 immune responses to combat parasites and 
helminths, as well as toxins and venoms [16, 17]. Parasites are pathogens very large 
in size that cannot be engulfed and eliminated by innate immune cells, and danger-
ous venoms/toxins might rapidly spread throughout the body. Therefore, the main 
aim of type 2 immune responses is to expulse away the pathogen from the body or 
destroy the toxins, thus avoiding their systemic dissemination and the lethal conse-
quences for the host. Aberrant type 2 immune responses, due to different and some-
times unknown etiologies, might lead to the development of allergic diseases such 
as asthma or food allergy as well as to skin diseases such as AD [2, 4, 18]. Initially, 
AD was regarded as a Th2-mediated disease; however, recent findings showed that 
type 2 innate lymphoid cells (ILC2s) and other innate immune and effector cells also 
contribute to the orchestration of these responses. Therefore, the term type 2-medi-
ate disease is more adequate according to our current knowledge [19, 20].
Different cell subsets from both arms of the immune system, as well as tissues 
and non-hematopoietic cells, directly contribute to the orchestration of type 2 
immune responses, both locally and systemically [19]. Under normal condi-
tions, the presence of helminths or toxic substances triggers the production of 
large amounts of alarmins such as TSLP, IL-33, or IL-25 by epithelial cells (ECs). 
Alarmins directly activate and expand ILC2s by mechanisms depending on IL-7 
and condition the capacity of dendritic cells (DCs) to induce T helper (Th)2 and 
type 2 CD8+ cytotoxic T-cell (Tc2) responses by mechanisms depending on IL-4 
[21]. Activated ILC2s, Th2, and Tc2 cells produce type 2 cytokines such as IL-4, 
IL-13, or IL-5, which contribute to the recruitment and activation of different 
effector cells such as eosinophils, basophils, and mast cells to the inflamed tissue. 
Type 2 cytokines also participate in the activation of non-hematopoietic cells and 
tissues, which in cooperation with the activated immune effectors’ cells aim at 
eliminating the potentially dangerous invading pathogen/toxin, avoiding systemic 
dissemination.
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2.3 Dendritic cells connect innate and adaptive immune responses
DCs are antigen professional presenting cells (APCs) that link innate and adap-
tive immune responses [2, 22]. They are localized in all peripheral tissues, circulat-
ing in the blood and lymphoid organs. Their primary function is to scan and collect 
antigens in the periphery (skin, airways, or gut), process these antigens into peptide 
fragments, and present them in the context of MHC molecules to naïve T cells. DCs 
express costimulatory molecules and produce polarizing cytokines, which, together 
with their migratory capacity, empower them as the essential APCs in the priming 
of T cell responses [15, 23].
Depending on the type of encountered antigen and the signals that DCs receive 
in the periphery and during the travel to the lymph node, they can generate dif-
ferent types of effector CD4+ T cells [24, 25]. When DCs encounter intracellular 
pathogens (viruses or bacteria), they produce large amounts of IL-12 and induce 
IFN-γ-producing Th1 cells that in turn activate NK cells and CD8+ T cells to combat 
these infections. Aberrant Th1 responses also associate other autoimmune diseases 
[25]. In contrast, extracellular pathogens (bacteria or fungi) condition DCs to 
produce large quantities of IL-23, IL-1β, TGF-β, and IL-6, thus promoting the gen-
eration of IL-17A-producing Th17 cells that contribute to neutrophilic infiltration to 
eliminate these pathogens. Alterations of Th17 responses have been associated with 
different autoimmune diseases and psoriasis [26]. Under certain circumstances, 
mucosal DCs can also generate IL-9-producing Th9 or IL-22-producing Th22  
cells, which contribute to activate mast cells and to promote epidermal hyperplasia, 
respectively [24, 26]. As above discussed, the presence of parasites or venoms acti-
vates ECs and instructs DCs to polarize Th2 cells producing large amounts of type 
2 cytokines such as IL-4, IL-13, IL-5, or IL-9. Aberrant Th2 responses are the main 
drivers of allergic diseases and AD [12, 25]. In addition to these effectors CD4+ 
T-cell responses, DCs can also generate regulatory T cells with potent suppres-
sive capacity, which play a crucial role in keeping homeostasis avoiding excessive 
immune activation and tolerance induction [2, 3, 18, 27].
In humans, blood DCs are classified into two main groups: (i) myeloid dendritic 
cells (mDCs) and (ii) plasmacytoid dendritic cells (pDCs) [28]. According to the 
expression of specific markers, mDCs can be further divided into type 1 mDCs and 
type 2 mDCs [28–30].
pDCs are the primary producers of type I IFNs and are essential in antiviral 
responses, whereas different subsets of mDCs contribute to the orchestration of 
different types of immune responses. Both mDCs and pDCs are different pheno-
typic and functional DC subsets that cooperate to integrate and mount immune 
responses.
In the healthy skin, under non-inflammatory conditions, the number of DCs 
is relatively low with a clear predominance of epidermal and dermal Langerhans 
cells (LCs) [12, 31]. In contrast, the number and composition of DC subsets in the 
lesional skin of AD patients are altered with significant infiltration of inflamma-
tory dendritic epidermal and dermal cells (IDECs and IDDCs, respectively) [12, 
31]. DCs in the skin of AD patients express high levels of the high-affinity receptor 
for IgE (FcεRI), which might play a critical role in the priming and expansion of 
memory T cells. Besides, after IgE-FcεRI cross-linking, DCs produce a plethora of 
chemokines that add to the recruitment of Th2 cells and other inflammatory cells 
into the skin, thus enhancing inflammation. IDECs can also migrate to lymph node 
and polarize and increase the frequency of Th2 cells but also Th1, Th17, and Th22 
as observed during the most chronic phases of AD [12, 31]. Overall, DCs play an 
essential role in the initiation and maintenance of type 2 immune responses in the 
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context of AD as well as in the generation of other Th cell subsets detected during 
the chronic phases and in different phenotypes of AD patients.
2.4 The immunopathogenesis of AD
The knowledge of the immunological mechanisms involved in the pathogenesis 
of AD has significantly improved over the last years. There are three phases in AD 
development involving different cytokines and cellular signatures that account for 
the clinical manifestations of the disease: (i) initial non-lesional stage, (ii) acute 
stage, and (iii) chronic stage.
2.4.1 Initial non-lesional stage
The structural integrity and permeability to environmental insults are severely 
compromised in susceptible patients displaying skin barrier defects [5, 10]. These 
skin alterations might be originated due to different factors including genetic 
susceptibility (mutations in filaggrin and/or other key genes for stratum corneum 
and skin integrity), alterations in tight junction proteins (TJ), dysregulation of skin 
lipid composition, changes in pH, altered microbiome, high transepithelial water 
loss (TWEL), or high susceptibility to infections and irritants. These skin barrier 
defects allow the penetration of large amounts of allergens, pathogen-derived anti-
gens, and/or other environmental insults into the lower epidermal layers, leading to 
the activation of keratinocytes [7]. Skin DCs uptake the encountered allergens and 
migrate to the closer lymph nodes conditioned by keratinocyte-derived alarmins 
such as TSLP, IL-33, or IL-25. These alarmins also activate tissue-resident ILC2s, 
which produce large amounts of type 2 cytokines facilitating DC migration and 
recruitment of inflammatory cells into the skin [7, 10]. Under these circumstances, 
DCs polarize naïve CD4+ T cells into allergen-specific Th2 cells by mechanisms 
depending on IL-4. The clonal expansion and activation of Th2 cells significantly 
contribute to IgE class-switching at the B level. The generated IgE+ B cells differen-
tiate into plasma cells that produce large amounts of allergen-specific IgE antibodies 
that bind to the surface of mast cells and basophils, leading to the allergic sensitiza-
tion [2, 4]. The induced Th2 cells home back and infiltrate the skin through lymph 
and circulation, leading to the classical skin inflammation observed of this initial 
stage even in the absence of skin lesions.
2.4.2 Acute stage
During the acute stage of AD, activated Th2 cells and ILC2s produce large 
amounts of IL-4, IL-13, IL-31, and IL-5 [12, 24]. IL-5 favors eosinophil recruitment 
into the skin and IL-31 in cooperation with IL-4 and IL-13 play a critical role in 
itching, thus initiating the vicious circle of itching-scratching that contributes to 
increase the damage of the already altered skin barrier and to enhance inflamma-
tion [12]. IL-31 directly act on sensory neurons, but it also promotes the growth 
of sensory nerves and skin hyperinnervation [32, 33]. IL-4 not only contributes 
to increasing the expression of IL-31 [34] but also together with IL-13 to sensitize 
neurons to a large variety of pruritogens such IL-33 and TSLP that increase after 
scratching, thus potentially contributing to chronic itch [32]. IL-4 and IL-13 also 
directly act on keratinocytes by inhibiting their differentiation, the production of 
antimicrobial peptides (AMPs), and altering lipid metabolism, thus enhancing 
barrier disruption. Six IL-13-activated keratinocytes produce an extensive battery 
of chemokines such as CCL17 (TARC), CCL26 (eotaxin), CCL18, and CCL22. In 
cooperation with the increment of vascular permeability induced by IL-4 through 
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the increased of vascular cell adhesion molecule-1 (VCAM-1) on vascular endothe-
lial cells, a massive infiltration of different types of inflammatory cells and vascular 
leakage takes place [5, 7]. Collectively, all these mechanisms account for the typical 
clinical symptoms of the AD acute stage, including itching and eczema lesions 
characterized by edema and spongiosis.
2.4.3 Chronic stage
The perpetuation of this predominant type 2 inflammation might lead to the 
chronicity of the disease [5]. In this phase, inflammation increases and persists 
due to constant activation of keratinocytes, vascular endothelium, inflammatory 
cells, and chronic itching. Remarkably, in the chronic stage, other Th cell subsets 
including IFN-γ-producing Th1, IL-17-producing Th17, and IL-22-producing Th22 
are also infiltrating the skin lesions [11, 15]. Depending on the AD subtypes, the 
relative frequency and contribution of these inflammatory Th cell subsets might 
vary significantly [11, 35, 36]. For example, in Asian AD patients as well as in some 
AD children subtypes, IL-17-producing Th17 cells might contribute to parakera-
tosis resembling typical features of psoriasis. In European-American, African 
American, and children AD patients, IL-22 produced by Th22 cells in cooperation 
with high levels of type 2 cytokines IL-4/IL-13 reinforce defective barrier func-
tion. It also enhances keratinocyte proliferation and promotes epidermal hyper-
plasia, leading to the lichenification and chronic itching typical of chronic stage 
[5, 10, 11, 35, 36].
3. Clinical features of AD
Although AD frequently appears during childhood and tends to subside as the 
patient grows, there is a considerable number of patients who persist in adulthood.
Recently, adult-onset and elderly onset phenotypes have been described [37, 38].
The essential features of AD are eczematous lesions and pruritus. Former can be 
acute, subacute, or chronic.
The clinical presentations, the lesion type and its distribution, are age specific, 
and this is a crucial aspect to consider when examining patients so as not to miss 
diagnose them.
AD phenotypes can be stratified according to multiple characteristics. One of 
the most used is the age-related clinical stratification, which classifies patients into 
four groups [39].
Infantile AD: Patients from 0 to 2 years present with an acute form of eczema, 
which typically affects cheeks, face, sparing nasal-labial triangle, scalp, trunk, and 
extensor surfaces of the limbs. The napkin area is typically respected.
Children AD: From 2 to puberty patients show subacute-to-chronic eczema that 
affects the flexural folds, dorsal aspects of the limbs, perioral area, and napkin area.
Adult AD: Adults typically present with a chronic or lichenified (Figure 1) and 
symmetric eczema that involves flexures, wrist, ankles, eyelids, and cheeks. In 
patients with a longstanding AD, a selective involvement of the neck and dorsal 
aspect of the hands is frequent, showing lichenified brown lesions that resemble 
dirt (Figure 2).
Elderly AD: AD in elderly presents with widespread chronic eczematous lesions 
with significant itch (Figure 3). It is usually misdiagnosed as cutaneous T-cell 
lymphoma, allergic contact dermatitis, or other types of eczema. Further informa-
tion is needed regarding the exact clinical presentation so as not to underestimate its 
real prevalence.
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Patients can also be classified according to the age of onset [39]. Bieber et al. 
proposed six phenotypes, which included very early-onset (3 months–2 years), 
early-onset (2–6 yeas), childhood-onset (6–14 years), adolescent-onset 
(14–20 years), adult-onset (20–60 years), and very late-onset (>60 years). The 
majority of patients fall into the first group; however, adult-onset is a recently 
identified group, which represents about 20% of all the cases. The latter group 
includes two subsets, those with AD in the past and a long period of remission 
and those with a very late-onset.
It is important to consider that patients can present not only with widespread 
lesions but also with localized or morphologically distinct phenotypes.
Localized variants include selective eczema of the nipples, hands, eyelids, peri-
auricular area, cheilitis, subnasal region, and genital area. The head and neck type 
are typical of the adult group and show involvement of the upper trunk and scalp.
Morphological variants comprise the follicular type, which presents as aggre-
gated follicular papules, the papulo-lichenoid variant, the prurigo variant that 
resembles a prurigo nodularis, the nummular variant, and erythroderma [5, 37, 40] 
(Figure 4).
Figure 1. 
Lichenified lesions on the posterior part of the legs.
Figure 2. 
Chronic eczema in an adult patient with lichenified brown lesions on the lateral aspects of the neck that 
resemble dirt.
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Silvestre Salvador et al. [37] recently described and classified the clinical forms 
of presentation of AD in adult patients. They identified 11 groups: lichenified/
exudative flexural dermatitis, head-and-neck eczema, seborrheic dermatitis-like 
dermatitis, portrait dermatitis, hand eczema, generalized eczema, prurigo nodu-
laris, nummular eczema, erythroderma, psoriasiform dermatitis, and multiple 
lesions of lichen simplex.
3.1 Diagnostic of AD
The diagnostic of AD is based on clinical features since no specific biomarkers 
or histological hallmarks exist. It relies on the morphology and distribution of the 
lesions, clinical history, and other clinical signs.
Multiple sets of diagnostic criteria have been developed since 1980 when 
Hanifin-Rajka proposed the first, which included major and minor features. It 
requires 3 out of the four major and 3 out of the 23 minor criteria to establish a 
diagnosis. Later, the “United Kingdom Working Party” settled a set, which followed 
the essence of the Hanifin-Rajka’s, but adapted it for epidemiological and clinical 
studies [5].
In 2003, Eichenfield et al. [41] revised the original criteria and elaborated a set 
dividing features into essential, important, and associated (Table 1). It also includes 
Figure 3. 
Widespread eczema in an elderly patient.
Figure 4. 
Erythrodermic variant of AD.
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exclusionary criteria to help with the differential diagnostic. Probably, these criteria 
are the most used in a clinical setting.
In 2016, Liu P et al. [42] proposed an easy-to-use set for adolescents and adults. 
They based the diagnostic on the presence of symmetric eczema for more than 6 
months associated to one or more of the following: family or personal history of 
atopic-related diseases, eosinophilia, and elevated total or specific IgE.
Diagnostic criteria for SD
Essential 
features (must 
be present)
Pruritus
Eczema (acute, subacute or chronic) Typical 
morphology 
and 
age-specific 
patterns
Facial, neck, 
and extensor 
involvement 
in infants and 
children
Current or 
prior flexural 
lesions in any 
age group
Sparing of 
groin and 
axillary regions
Chronic or relapsing
Important 
features (seen 
in most of the 
cases, adding 
support to the 
diagnosis)
Early onset
Atopy Personal and/or family history
IgE reactivity
Xerosis
Associated 
features (help 
to suggest the 
diagnosis of 
AD but are too 
non-specific 
to be used for 
defining or 
detecting AD)
Atypical vascular response
Keratosis pilaris/pityriasis alba/hyperlinear palms/ichthyosis
Ocular or periorbital changes
Other regional findings
Perifollicular accentuation/lichenification/prurigo lesions
Exclusionary 
conditions
Scabies
Seborrheic dermatitis
Contact dermatitis
Ichthyosis
Cutaneous T-cell lymphoma
Psoriasis
Photosensitivity dermatoses
Immune deficiency diseases
Erythroderma of other causes
Adapted from Eichenfield et al. [41].
Table 1. 
Diagnostic criteria proposed by Eichenfield et al. in 2003.
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3.2 Approach to the patient with AD
When considering the diagnostic of AD, it is crucial making a thorough clini-
cal history, which includes information regarding the chronicity of eczema, the 
presence of itch, and the personal and family history of atopy. In children, AD is 
one of the first diagnostics to consider, while in the adult population, probably due 
to a lack of familiarity with adult-onset disease and even when dealing with patients 
with a compatible clinical picture, the first diagnostic suspicion tends to be contact 
dermatitis. Physical examination is also mandatory to determine the morphology 
and distribution of the lesions, which can help to consider or even establish the 
diagnostic [37].
There are controversies regarding complementary tests, which are useful at rul-
ing out differential diagnostics. According to the AAD guidelines, AD is a diagnos-
tic of exclusion and should only be established after excluding other diseases [43].
Patch testing should be considered in patients with adult-onset disease, those 
with a chronic disease who fail to respond to adequate treatment, patients with 
atypical or changing distribution, as well as patients with patterns suggestive of 
allergic contact dermatitis. Patch test should always be assessed according to clinical 
history to determine the relevance of the results [37].
The utility of the prick test is somewhat controversial. A prick for airborne 
allergens could be useful in adults with an airborne pattern eczema involving the 
face, particularly eyelid area, neck, and exposed regions of upper limbs. Testing for 
food allergies might be of help in pediatric patients with generalized eczema that 
worsen when exposed to certain foods, but also in adult patients who are sensitized 
to pollen, as pollen-related foods can cause cross-reaction with airborne allergens 
and trigger flares. Ruling out a protein contact dermatitis could be indicated in 
patients with chronic hand eczema that flares when handling food [37, 44].
A blood test is not mandatory but can be useful at supporting the diagnostic of 
AD. High IgE levels and eosinophilia are frequent in these patients. Other param-
eters such as lactate dehydrogenase (LDH), serum thymic activation regulator 
chemokine (sTARC)/CCL17, CCL27, cationic eosinophilic protein (CEP), and anti-
transglutaminase antibodies may provide with information regarding the severity 
or helping in the differential diagnostic (see biomarkers).
Although the histopathologic picture of atopic dermatitis does not differ from 
other types of eczema, a skin biopsy may help rule out other diagnostics such as 
cutaneous T-cell lymphoma (CTCL), psoriasis, or drug reactions [37].
Including a simple blood test with hemogram, liver function, renal function, 
LDH, total IgE (and specific if the clinical history suggests it), IgA, and antitrans-
glutaminase antibodies would be reasonable during the initial diagnostic workup. 
Indications for a patch test and prick test are those specified before.
3.3 Assessment of the disease severity and impact on the quality of life
After setting up the diagnostic of AD, it is essential to assess the severity of the 
disease and its impact on patient’s quality of life.
3.3.1 Severity
Several scales evaluate the severity; some of them include just objective signs, 
while others also include subjective patient’s symptoms.
Most of the scales are composite score systems, which assess different aspects of 
the disease (Table 2).
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The most used in European countries is the Scoring of Atopic Dermatitis 
(SCORAD). It first evaluates the body surface area (BSA) affected and then gives a 
score from 0 to 3 for each of the following clinical features: erythema, edema, exco-
riation, swelling/crusts, lichenification, and xerosis. Finally, the patient is asked 
to rank pruritus and sleeplessness from 0 (best situation) to 10 (worst situation), 
giving a total score that ranges from 0 to 103, being the latter the most severe. It is 
considered a score from 0 to 25 as a mild disease, 25–50 as moderate, and 50 and 
above as severe.
Eczema area and severity index (EASI) is a scale based on PASI score.
EASI is a more objective tool, which does not include the patient’s symptoms, 
which is widely used in the US and also in the setting of most of the clinical trials. 
It divides the body into four parts, head and neck, trunk, upper limbs, and lower 
limbs. The first step is to assess the affected surface in each of the zones and then 
score erythema, edema, excoriation, and lichenification from 0 to 3. Each score is 
multiplied by a specific quotient, obtaining a final number that ranges from 0 to 72.
The patient-oriented eczema measures for eczema (POEM) is a symptom score 
that measures the subjective symptoms of the patient. The final result ranges from 0 
to 28, being the latter the worst.
Severity Quality of life
Scale Score Description Msc Scale Score Description Msc
SCORAD 0–103 <25 mild
25–50 moderate
>50 severe
8.7 HADS 0–42 
(A/D)
0–7 normal
8–10 
borderline 
abnormal
11–21 
abnormal
N/A
EASI 0–72 ≤7 mild
>7–21 moderate
>21 severe
6.6 DLQI 0–30 0–1 no effect 
at all on 
patient’s life
2–5 small 
effect
6–10 
moderate 
effect
11–20 very 
large effect
21–30 
extremely 
large effect
4
IGA 0–4 0 clear
1 almost clear
2 mild
3 moderate
4 severe
N/A
Symptoms
POEM 0–28 0–2 clear or almost clear
3–7 mild
8–16 moderate
17–24 severe
25–28 very severe
3.4
VAS 
pruritus
0–10 The higher the score, the more severe the pruritus 2–3
VAS sleep 0–10 The higher the score, the more sleeplessness 2–3
SCORAD, scoring of atopic dermatitis; EASI, eczema area and severity index; HADS, hospital anxiety and 
depression scale; DLQI, dermatology life quality index; POEM, patient-oriented eczema measures for eczema; VAS, 
visual analogue scale; MSC, minimal significant change.
Table 2. 
Scales of severity and quality of life.
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Investigator global assessment (IGA) is an easy-to-use scale that describes the 
overall appearance of the lesions and scores the severity from 0 to 3, 0 means a 
clear, 1 almost clear, 2 mild, 3 moderate, and 4 severe disease. Unlike the other three 
scales, it is not a validated score, but a global assessment of the disease.
3.3.2 Quality of life
Assessing disease impact on patient’s quality of life is as important as evaluating 
the severity.
There are over ten disease-specific tests available for AD and more than 25 
generic instruments that can be used in AD [45]. Each of these tools focuses on 
different aspects of the disease, not only regarding the patient but also their family 
or close relatives. Table 2 shows two of the most used scales in assessing QoL.
There are also non-disease-specific questionnaires that study the school or work 
productivity, focusing not only on work absenteeism but also on presenteeism. One 
of the most known is WPAI (Work Productivity and Activity Impairment), which 
is composed of 6 questions regarding the effect of the disease on the ability to work 
and perform regular activities.
3.4 Biomarkers in AD
Biomarkers are an interesting matter of debate nowadays. Although there is 
plenty of literature on the topic, the utility and applicability of them still present 
some concerns.
A biomarker is a common term used across the atopic dermatitis literature. 
There are two definitions proposed by the World Health Organization (WHO) 
and by the National Institutes of Health (NIH) biomarkers definition group, 
which largely overlap. The WHO defines it as “any substance, structure or process 
that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease. Biomarkers can be classified into markers of 
exposure, effect and susceptibility” [46], while the NIH definition is “a character-
istic that is objectively measured and evaluated as an indicator of normal biologi-
cal processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention.” [47].
There are two types of biomarkers, those used for selection or stratification of 
the patients and those used for monitoring the clinical response.
The former includes screening, diagnostic, prognostic, and predictive biomark-
ers, while the latter comprises severity and pharmacodynamic markers [48].
Screening biomarkers: Several biomarkers could help in the screening. Mutations 
in the filaggrin gene are present in up to 30% of the AD patients. R501X and 
2282del4 are the most frequent and are dose dependent. These may predict a higher 
risk of eczema herpeticum and an earlier onset of the disease [49, 50].
Other parameters, such as high levels of cord IgE, infantile a-lymphotoxin and 
FcεRI-β during pregnancy, as well as high TEWL and SPINK5/LEKTI, could also be 
useful as screening biomarkers [48].
Diagnostic biomarkers: Although the AD diagnostic is clinical, some biomarkers 
could help to decant the balance toward AD. Total serum IgE is a useful parameter 
for dividing patients into intrinsic and extrinsic phenotypes. Up to 20% of patients 
belong to the intrinsic group, with normal levels of IgE. Consequently, it is an 
unreliable biomarker for diagnostic purposes.
Filaggrin and leukotriene B4 serum levels could be two valuable biomarkers, as 
they have been shown to differ from healthy controls significantly. AD patients tend 
to present higher levels of the former and lower of the latter [51].
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Prognostic biomarkers: The purpose of these markers is to estimate the course and 
evolution of the disease. The only known parameter in this group is the presence of 
some mutations in the filaggrin gene, which could determine a more severe course 
of the disease [48].
Predictive biomarkers: This group identifies patients that are most likely to 
respond to a specific therapy. Currently, as new targeted therapies are arising, 
there is an evident lack of such biomarkers that help to classify and assign a given 
treatment.
Recently, Wollenberg et al. described that higher levels of serum periostin and 
dipeptidyl-dipeptidase 4 (DDP4) conditioned a better response to anti-IL-13 thera-
pies. On the other hand, the presence of single-nucleotide polymorphism (SNP) in 
the gene promoter region of UGT1A9 is related to low mycophenolate blood levels, 
and thus a worse response to the drug. Increasing the dose could solve this lack of 
response [48, 52].
Pharmacodynamic biomarkers: These biomarkers might be relevant when plan-
ning therapeutic regimens for AD patients. Although scarcely used, these may help 
to personalize and enhance efficiently of some systemic treatments.
Tacrolimus is metabolized by CYP3A4 and CYP3A5. CYP3A4*22 and CYP3A5*3 
are seen in slow metabolizers, leading to high blood levels. CYP3A5*3 is associated 
with a fast metabolism, and it entails low blood levels.
Increased activity of UGT1A9 caused by SNPs can lead to a lack of response to 
mycophenolate due to low blood levels [48].
Azathioprine (AZA) adverse events can be predicted by genotyping thiopurine 
methyltransferase. The risk of myelotoxicity and liver toxicity can be assessed by 
monitoring AZA metabolites 6-thioguanine nucleotides and 6-methylmercaptopu-
rine ribonucleotides [53].
Severity biomarkers: Most of the known biomarkers belong to this group. It is 
essential to distinguish between those biomarkers studied in longitudinal studies, 
which give information of the evolution of the parameter along the time and in 
response to the treatment and those derived from cross-sectional studies, which 
provide with an objective measure of severity at a given moment. Lately, most of 
the efforts on biomarkers are focused on identifying combinations of biomarkers, 
which better predict the severity of the disease [54]. Thijs et al. proposed two panels 
of biomarkers, the first of them [55] is made up of TARC, PARC, IL-22, and sIL-2R 
and correlates much better with the disease severity than each of the biomarkers 
alone. The same group elaborated a second panel composed of TARC, IL-22, and 
sIL-2R, which allowed to predict EASI with a sensitivity of 100% and specificity of 
88.9% [56].
Table 3 summarizes these biomarkers.
3.5 Risk factors
Several factors have been associated with the development of AD. Some are 
regarded as risk factors, while others have a protective role.
Atopy family history and loss-of-function mutations in the gene of filaggrin 
are two clear risk factors for AD. About 70% of the patients have a positive family 
history of atopic diseases. The OR for children with one parent affected, compared 
to those without any, is 2–3, while those with the two parents affected it is 3–5.
FLG-null mutations condition a more severe, persistent and early-onset disease 
with a higher tendency to eczema herpeticum [43, 60].
Kelleher et al., have recently described that skin barrier dysfunction at 2 days 
and 2 months of life, as well as neonatal adiposity, increases the risk of AT during 
the first year of life.
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An increase in the transepidermal water loss (TWEL) at 2 days and 2 months 
of life conditions to a higher incidence of AD at 6 and 12 months, regardless of the 
FLG mutations, family history, or presence of itchy flexural rash at 2 months [61].
Besides, a fat mass of the 80th percentile or higher at day two might also be a 
predictor for AD at 6 and 12 months of age [62].
Risk and protective factors are summarized in Table 4.
3.6 Comorbidities
Compared to non-AD patients, patients with AD have a higher incidence of 
comorbidities that include not only the atopic march associated diseases but also 
other disorders. The sequential appearance, since early ages, of atopic dermatitis, 
allergic rhinitis, asthma, and rhinitis is known as the atopic march and is frequently 
seen together in patients with AD. Other diseases as chronic pulmonary disease, 
chronic rhinosinusitis, urticaria, autoimmune disorders, conjunctivitis, eosino-
philic esophagitis, nasal polyposis, obesity, bacterial, fungal, and viral infections 
are also seen more frequently in these patients. Neuropsychiatric disorders includ-
ing anxiety, depression, attention deficit hyperactivity disorder (ADHD), and sleep 
disturbances are also more prevalent in AD patients than controls.
In a study from the US, authors showed that not only these diseases are more 
frequent among AD patients but also that are more likely to occur in those with 
severe disease compared to less severe patients [64].
Finally, an increase in cardiovascular events has been reported in these patients. 
Andersen et al. showed that this higher incidence was due to an increased burden of 
comorbidities and detrimental lifestyle behavior [65]. Brunner et al., later suggested 
Biomarker Cross-
sectional 
studies
Longitudinal 
studies
Conclusion
sTARC/CCL17 Yes Yes Potential biomarker for severity and 
evolution of the disease. Best characterized 
biomarker [54]
Total IgE Yes Yes Could be a good biomarker for the severity 
but not for the disease evolution [54]
cTACK/CCL27 Yes No Potential biomarker for severity [54]
ECP Yes Yes Questionable value as a severity and 
evolution biomarker [54]
EDN Yes No Potential biomarker for the severity. Could 
be a predictor of relapse in severe AD [57]
LDH Yes No Potential biomarker for severity [54]
Periostin Yes No Good correlation with disease severity and 
chronicity [58]
IL-18 Yes No Potential biomarker for severity [54]
E-selectin Yes No Potential biomarker for severity [54]
CD30 Yes No Potential biomarker for severity [54]
IL-2R, IL-4R, IL-31, and 
tryptase
Yes No May correlate with severity. More studies 
needed [54, 59]
ECP, eosinophil cationic protein; EDN, eosinophil derived neurotoxin; LDH, lactate dehydrogenase.
Table 3. 
Severity biomarkers.
Dermatitis
14
that inflammatory mediators involved in the atherosclerosis development such as 
CCL7, IL16, PI3, and E-selectin would be responsible for this increase in the inci-
dence and that they were strongly related to the severity of cutaneous inflammation 
rather than obesity or lifestyle behavior [66].
4. Treatment
There is not a single approach to the treatment of patients with AD. It is a 
patient-tailored treatment, which depends on the patients’ predominant symptoms 
and past medical history.
The therapy aims to control the skin barrier disruption, the altered immune 
response, and microbial infections, as well as pruritus [67].
4.1 Topical treatment
Baseline treatment for AD is moisturizers to help to prevent water loss and 
maintaining skin hydration. Emollients, humectants, or occlusive agents should 
be used as a maintenance treatment for all patients with AD. The recommended 
weekly amount is 250-500 g in adult patients and about 100 g in children.
The use of emollients in inflamed skin is poorly tolerated, it is advised to treat 
the inflammation first with topical treatments and then apply the moisturizer, at 
least twice a day [68].
According to the European guidelines for the treatment of AD, an “emollient” 
is a “topical formulation with vehicle-type substances lacking active ingredients,” 
whereas “emollients plus” refers to “topical formulations with vehicle-type sub-
stances and additional active, non-medicated substances” and are meant to target 
specific lesions [68].
Simpson et al. showed that strict emollient therapy from birth in children at a 
high risk of developing AD (a parent or full sibling with AD, asthma, or allergic 
rhinitis) was a practical preventive approach [69].
Risk factors • Family history
• Loss-of-function mutations in FLG gene
• Parents educations: higher education–higher risk
• Urban zones
• Domestic animals: cat increases the risk
• Indoor exposition to chemicals
• Environmental tobacco smoke
• Traffic exhaust
Not risk factors • Age at which food is introduced
• Socioeconomical status
• Type of delivery
• Birth weight
Protective factors • Hydrolyzed formulas or exposition to probiotics
• Exposition to endotoxin, dogs and farm animals at early ages
• Unpasteurized milk
• Helminthic infections
Table 4. 
Risk and protective factors for developing AD [43, 60, 63].
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It is also essential to keep optimal skin hygiene. There are some controversies 
regarding daily bath; however, a short bath of up to 5 minutes with bath oils or non-
irritant and low-allergen formulas, to eliminate crusts and bacterial contaminants, 
is advised.
Adding antiseptics to the bathwater may be useful in cases that show bacterial 
superinfection [68].
4.2 Topical anti-inflammatory treatment and phototherapy
Topical corticosteroids and calcineurin inhibitors are the treatments of choice 
for flares in patients with mild disease (SCORAD <25/EASI <7). Moderate or 
recurrent cases (SCORAD 25–50/EASI 7–21) require proactive therapy with more 
potent corticosteroids, calcineurin inhibitors, or phototherapy. The proactive 
scheme consists of daily application of emollients to unaffected skin combined with 
intermittent use (twice weekly) of the anti-inflammatory drug in usually affected 
sites. Studies have proven long-term security and efficacy in reducing relapses [68].
The amount of topical anti-inflammatory drugs should follow the fingertip unit 
rule (0.5 g), which is the adequate amount for application to two adult palm area 
(approx. 2% of adult body surface area).
Phototherapy, UVA1 and narrow-band UVB, has shown its long-term efficacy 
in AD in multiple studies. Except for high doses of UVA1, it is not indicated during 
flares, but in pruritic and lichenified chronic forms. Most of the times, concomitant 
use of emollients and/or anti-inflammatory therapy is advised.
Severe patients (SCORAD > 50/EASI > 20) require a more aggressive approach 
with immunosuppressive agents or biologicals.
Crisaborole is a topical phosphodiesterase 4 (PDE4) blocker approved in the US 
for the treatment of mild-to-moderate AD in patients 2 years old and older, which 
has shown to be more effective than the vehicle alone. There are no comparative 
studies with topical corticosteroids or calcineurin inhibitors [67, 68, 70].
Topical Janus kinase inhibitors are still not licensed for the treatment of AD, but 
they are in the pipeline of multiple laboratories that are currently conducting phase 
II studies.
4.3 Systemic treatment
Antihistamines: Although the use of systemic antihistamines is widespread in 
the treatment of pruritus in AD patients, the scarce studies available have shown 
a minimal effect on decreasing pruritus. First-generation anti-H1 have a sedative 
effect that can help in decreasing nocturnal itch, but with impaired sleep quality.
Although there is not enough evidence to support the use of both first and 
second-generation anti-H1, the former should be used with caution in patients with 
AD and sleep disturbances.
Corticosteroids: Systemic corticosteroids have been widely used for the treatment 
of AD. Both European and American guidelines recommend to use them for short 
periods (up to 7–10 days), for treating acute flares, at a daily dose of 0.5 mg/kg. 
Long-term use is discouraged due to side effects. A possible rebound after with-
drawal should be considered when treating these patients [71].
Immunosuppressive agents: These are the drugs of choice for most of the 
moderate-to-severe patients. Cyclosporine A (CsA) is the only approved systemic 
drug for the treatment of AD in Europe. It has shown its efficacy both in adults 
and children, although it is not approved under 18 years old. CsA is indicated in 
chronic, severe cases of AD for a maximum of 2 years in a row. Is a fast-acting 
drug with an onset of the efficacy within the first 2 months, but it has a rapid 
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relapse once stopped. The most used doses range from 2.5 to 5 mg/kg/day. There 
is no clear consensus on how to start, some authors opt for starting at low doses 
(2.5 mg/kg/day) and increase the dose 0.5 mg/kg/day every 2–4 weeks depending 
on the clinical response, up to a maximum of 5 mg/kg/day. Some others prefer 
starting at high doses and reduce the dose until the minimum efficacious dose. 
The main concerns regarding the use of this therapy are toxicities and interac-
tions. Nephrotoxicity is the main side effect, which is more likely to occur in doses 
over 5 mg/kg/day, elderly patients and previous renal impairment. Patients under 
treatment with CsA are advised to take blood pressure regularly and monitor for 
renal parameters [71].
Other immunosuppressants such as methotrexate (15–25 mg/week), azathio-
prine (1–3 mg/kg/day), and mycophenolate mofetil (up to 3 g/day) are used off-
label. These tend to have a slower onset of the effect, around 8–12 weeks, but with a 
more prolonged residual effect once the treatment is stopped [71].
No studies are comparing the efficacy of the three agents; however, Eckert et al. 
have recently shown that patients receiving mycophenolate mofetil required more 
oral corticosteroid than the other treatments, whereas those receiving CsA were the 
patients who needed the least [72].
Two studies compared the overall efficacy of methotrexate and azathioprine and 
concluded to be equivalent [73, 74].
It is essential to regularly monitor these patients for possible side effects, mainly 
liver toxicity.
Biological agents: Despite all the immunosuppressive armamentarium, some 
patients still show a lack of efficacy. Biologicals are highly effective therapies with 
an immunomodulatory effect that specifically target inflammatory cells or media-
tors. Most of the biologicals developed or in development for AD target cytokines of 
the T2 response.
Dupilumab is the first biological licensed for AD. It is a fully human monoclonal 
antibody that blocks a chain of the IL-4 receptor, which is common in the receptor 
for IL-4 and IL-13. It is approved as first-line therapy for adult moderate-to-severe 
AD who are candidates to systemic therapy. Clinical trials showed its efficacy and 
favorable safety profile on AD patients. Taking all the clinical trials together, about 
70% of the patients achieved an EASI 75 or higher with a time-to-full-clinical-
response of about 4 weeks. Pruritus showed a rapid response with an initial 
improvement at 2 weeks [71, 75].
Recent case series have observed a similar response [76].
It has been shown that dupilumab improves the AD inflammatory signature [77].
The main reported side effects were conjunctivitis and local reaction at the site 
of injection.
The recommended dose of dupilumab in adults is an initial dose of 600 mg fol-
lowed by 300 mg every 15 days. There is no need for complementary studies before 
starting the treatment.
Only patients with previous helminthic infections should receive specific treat-
ment before dupilumab.
Due to a lack of data, live and live attenuated vaccines should not be given cur-
rently with dupilumab. It is recommended to be up to date with immunization prior 
to the treatment. Contraindications include hypersensitivity to dupilumab or any of 
its excipients [78].
Currently, dupilumab is also licensed for asthma.
4.4 New treatments
Several other molecules are under investigation [70].
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4.4.1 Biologicals
Tralokinumab and lebrikizumab are fully human monoclonal antibodies that 
target IL-13. They have shown sustained clinical improvement in moderate-to-
severe AD patients in phase II studies with an acceptable safety and tolerability 
profile. Wollenberg et al. showed that patients with higher serum levels of periostin 
and DDP4 had a better response to tralokinumab compared to those with lower 
levels [52].
Tralokinumab has already begun phase III trials, whereas lebrikizumab has yet 
to start.
Nemolizumab, a humanized monoclonal antibody against the receptor A of 
IL-31, has also shown efficacy in phase II trials in patients with moderate-to-severe 
AD. IL-31 plays a role in the pathogenesis of AD and pruritus. The two phase 2 
clinical trial showed not only a rapid and maintained effect on pruritus but also AD 
scores (EASI and BSA) [79, 80].
Fezakinumab is a fully human monoclonal antibody against IL-22. The phase 2a 
clinical trial showed a sustained clinical improvement in severe AD patients [81].
Tezepelumab is a fully human monoclonal antibody that targets TSLP. In the 
phase 2a trial, a non-statistically significant improvement over placebo at week 12 
was observed [82].
There are contradictory papers regarding the efficacy of ustekinumab, a fully 
human monoclonal antibody against the p40 subunit shared by IL-12 and IL-23 
[83–88].
4.4.2 Small molecules
There are several small molecules in development for AD.
Apremilast is an oral PDE4 inhibitor approved for the treatment of obstructive 
pulmonary disease, plaque psoriasis, and psoriatic arthritis [89]. Small series of 
cases have shown its potential as a treatment for AD [90, 91].
Baricitinib, a JAK 1 and 2 inhibitors, abrocitinib and upadacitinib, selective JAK 
1 inhibitors, are currently running phase 3 trials. Phase 2 showed positive results 
regarding efficacy and safety for the three molecules [92].
Finally, delgocitinib, a small molecule that targets JAK 1, 2, 3 and TYK 2 demon-
strated rapid improvement in clinical signs and symptoms with a favorable safety 
profile, in a phase 2 trial [93].
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